Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Haridas B Rode"'
Autor:
Sudha Sravanti Kotapalli, Sri Satya Anila Nallam, Lavanya Nadella, Tanmay Banerjee, Haridas B Rode, Prathama S Mainkar, Ramesh Ummanni
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144018 (2015)
The purpose of this study was to provide a number of diverse and promising early-lead compounds that will feed into the drug discovery pipeline for developing new antitubercular agents. The results from the phenotypic screening of the open-source com
Externí odkaz:
https://doaj.org/article/f549b1fc5563467e9ccfaf1d70b27cd2
Autor:
Thrilokraj R., Rajeev V. Hegde, Arnab Ghosh, Akshay S. Limaye, Haridas B. Rode, Balasubramanian Sridhar, Ramesh B. Dateer
Publikováno v:
New Journal of Chemistry. 47:8268-8276
A sustainable and environmentally benign biogenic technique for one-step synthesis of Ni-NPs (NiC2O4·2H2O-NPs) using Portulaca oleracea (purslane) leaf extract has been disclosed for the first time.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56cc24242417f4105bbae35d7783a1cd
https://doi.org/10.1039/d3nj00988b
https://doi.org/10.1039/d3nj00988b
Autor:
Grace Kaul, Uttam B Karale, Abdul Akhir, Manjulika Shukla, Deepanshi Saxena, Haridas B Rode, Sidharth Chopra
Publikováno v:
Future Microbiology. 17:1475-1486
Background: Drug repurposing is a viable approach to expediting the tedious conventional drug discovery process, given rapidly increasing bacterial resistance. In this context, we have repurposed pyrvinium pamoate (PP) for its antibacterial activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4ea209b1c6a6b76b880a6431486a8d7
https://doi.org/10.2217/fmb-2022-0159
https://doi.org/10.2217/fmb-2022-0159
Autor:
Gangarajula Sudhakar, Chennam Ramu, T. Kumaraguru, M. Sridhar Reddy, Haridas B. Rode, Subhash Ghosh, Ch. Raji Reddy
Publikováno v:
Synthesis.
We have designed and developed an easily accessible advanced intermediate of ledipasvir that allowed late-stage cyclopropanation and difluorination, thereby providing a novel and more efficient process for the preparation of ledipasvir in the longest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6596518e673c5500ae2794d6afa5c367
https://doi.org/10.1055/s-0042-1751437
https://doi.org/10.1055/s-0042-1751437
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Supplementary Figure 2 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b33c46cc59f5c4a05c14a3e2762176c
https://doi.org/10.1158/0008-5472.22385273.v1
https://doi.org/10.1158/0008-5472.22385273.v1
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Supplementary Figure 4 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10c3adab8e6719a4afeccf3c429f681c
https://doi.org/10.1158/0008-5472.22385267.v1
https://doi.org/10.1158/0008-5472.22385267.v1
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small molecules to improve progression-free survival of patients with EGFR-mutated lung cancers. Second-generation EGFR inhibitors introduced to overcome acquired re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c57476dbb8bceb81527d4a605d7f2ff
https://doi.org/10.1158/0008-5472.c.6501170.v1
https://doi.org/10.1158/0008-5472.c.6501170.v1
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Supplementary Figure 3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dda31a666e50397a900ef397d1a01dd
https://doi.org/10.1158/0008-5472.22385270.v1
https://doi.org/10.1158/0008-5472.22385270.v1
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Supplementary Figure 1 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417bb50b9082366c7e5acc04c42b3a1e
https://doi.org/10.1158/0008-5472.22385276
https://doi.org/10.1158/0008-5472.22385276
Autor:
Daniel Rauh, Roman K. Thomas, Heidi Greulich, Tzu-Hsiu Chen, Yuki Yuza, Matthäus Getlik, Jeffrey R. Simard, Mirjam Koker, Matthias Rabiller, Lars Ruddigkeit, Jonathan Weiss, Johannes M. Heuckmann, Cecile Reuter, Vijaykumar G. Pawar, Sabine Klüter, Florian Fischer, Martin Peifer, Stefanie Heynck, Haridas B. Rode, Martin L. Sos
Supplementary Methods, Figure Legends 1-3 from Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b08756303c46561e6b36ae101b44aab
https://doi.org/10.1158/0008-5472.22385264.v1
https://doi.org/10.1158/0008-5472.22385264.v1